Overview of Abdal

Property	Description
Active ingredient	Aceclofenac
Form	Tablet (Oral preparation)
Pharmacological class	Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose	Symptomatic relief of pain and inflammation
Origin	Synthetic, Phenylacetic acid derivative

What Type of Medicine is Abdal and What is its Composition?

Abdal is a prescription-only medicine that functions primarily as a Nonsteroidal Anti-inflammatory Drug (NSAID). Its core identity is defined by its sole active ingredient, Aceclofenac. Chemically, Aceclofenac is a synthetic compound derived from the Phenylacetic acid derivative group, a structural feature associated with anti-inflammatory activity. The classification of Aceclofenac as an NSAID is based on its role in mitigating pain and inflammation.

As a single-ingredient product, Abdal provides a focused therapeutic effect, distinguishing it from combination medications. It is presented as an oral preparation, commonly a tablet within a solid matrix of excipients, a form designed for systemic use in adult patient groups. This presentation ensures the active compound is absorbed into the bloodstream to target internal sources of discomfort.

General Purpose and Pharmacological Action

The general therapeutic purpose of Abdal is to provide symptomatic relief by reducing the physical components of discomfort, namely inflammation and pain. It achieves this by acting as a Cyclooxygenase inhibitor (COX inhibitor), which is the key mechanism for reducing the synthesis of prostaglandins—chemical mediators that signal pain and cause swelling. The drug provides relief for inflammatory symptoms in various musculoskeletal conditions, supporting its general therapeutic utility. This primary analgesic effect is complemented by a potent anti-inflammatory effect and an associated antipyretic effect (fever moderation), enabling management of inflammatory episodes.

What side effects are possible with Abdal?

Possible side effects and safety information

The safety profile of Abdal (Aceclofenac), an NSAID, is structured by government regulatory agencies based on the prevalence and seriousness of documented adverse reactions. Adverse effects are officially classified into frequency categories: Common, Uncommon, Rare, and Very Rare.

Frequency-Classified Adverse Reactions

Classification	Examples of Documented Effects	System-Organ Class Focus
Common	Dyspepsia, Abdominal pain, Nausea, Dizziness, Increased hepatic enzymes.	Gastrointestinal, Nervous System
Uncommon	Flatulence, Gastritis, Rash, Urticaria, Increased blood urea/creatinine.	Gastrointestinal, Skin, Renal
Rare	Hypersensitivity, Anaphylactic reactions, Anaemia, Gastrointestinal bleeding/ulceration.	Immune System, Blood, Gastrointestinal

Documented Serious Safety Risks

Regulatory warnings highlight the potential for serious adverse reactions. These include potentially fatal events such as Gastrointestinal bleeding, ulceration, and perforation, as well as Arterial Thrombotic Events (e.g., myocardial infarction, stroke). Severe Skin Reactions, including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are documented as very rare risks. The risk of serious skin reactions is noted to be highest early in the course of therapy.

Population-Specific Constraints

The medicine is officially contraindicated for use during the third trimester of pregnancy due to the risk of fetal harm. Furthermore, it is not recommended for children or adolescents due to insufficient data. The official label notes an increased risk of serious adverse reactions, particularly GI complications, in older adults. Severe heart, hepatic, or renal failure also constitute official contraindications for use.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Abdal

This information describes the overdose profile for Abdal (Aceclofenac) exclusively as documented in government regulatory sources.

Property	Official Regulatory Documentation Statement
Documented overdose presentations	Manifestations typically include gastrointestinal signs such as nausea, vomiting, and epigastric pain. Central nervous system effects listed are dizziness, drowsiness, headache, and disorientation.
Physiological systems affected (as stated in label)	The primary systems affected may include the gastrointestinal tract (risk of bleeding), renal function (risk of acute failure), and hepatic function (risk of damage).
Population-specific overdose notes (if applicable)	Increased severity risk is officially noted in patients with pre-existing renal impairment and potentially higher risk of severe GI effects in elderly patients.
Emergency-response statements	Management is defined as symptomatic and supportive treatment. Activated charcoal should be considered within one hour of ingestion of a potentially toxic amount, or gastric lavage in adults with life-threatening exposure.
When immediate medical help is required	Seek immediate medical attention following suspected overdose; close clinical observation and hospital monitoring of renal and liver function are required to manage severe outcomes.

Overdose Classifications (High-Level)

Property	Official Regulatory Documentation Statement
Severity classification	Overdose can lead to severe systemic outcomes, including acute renal failure, liver damage, and serious gastrointestinal bleeding, or rarely, convulsions.
Overdose-context constraints	Regulatory information confirms that no specific antidote is known for this overdose.

Connection to the overall overdose profile: Regulatory documents define the Aceclofenac overdose profile by documenting common initial manifestations and explicitly detailing the potential for severe systemic damage. The guidance mandates the requirement to seek immediate medical attention and establishes that management is limited to supportive care, emphasizing the necessity of continuous clinical and laboratory monitoring of affected systems.

Therapeutic Uses of Abdal

What Abdal Treats: Main Uses and Benefits

Abdal is applied across domains where additional symptomatic support is needed to manage symptoms related to inflammatory or irritative states in adults. This medication is commonly used to help with physical discomfort and is used in contexts involving heightened systemic burden. The medication is used to address conditions presenting with systemic or localized discomfort.

The treatment is indicated for use in conditions characterized by periods of heightened symptoms, including chronic inflammatory joint diseases like Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. It may be part of symptomatic management in situations involving symptoms associated with acute or episodic changes, particularly those related to localized musculoskeletal discomfort. The medication is used for managing symptoms that interfere with daily comfort.

“The medication is used for managing symptoms that interfere with daily comfort.”

Abdal plays a role in managing symptoms that become more disruptive during flare-ups, such as chronic joint pain, swelling, and severe morning stiffness. This supportive relief contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Support for Symptoms of Pain and Stiffness
Abdal may assist with managing symptoms related to physical discomfort in chronic arthritic conditions, including symptoms that interfere with daily functioning.

Eligibility and Restrictions for Use

Abdal is officially documented for use in adults who meet specific health eligibility criteria. Its use is strictly contraindicated (prohibited) for several populations as defined by regulatory labeling.

Populations Excluded (Contraindicated)

Abdal must not be used in patients with established severe hepatic failure or renal failure. It is also contraindicated in individuals diagnosed with established cardiovascular diseases, including congestive heart failure (NYHA class II-IV), ischaemic heart disease, or cerebrovascular disease. Further prohibitions apply to those with active or a history of recurrent gastrointestinal haemorrhage or peptic ulcers, and patients with known hypersensitivity to the medicine or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

Restricted and Age-Related Use

The medicine is contraindicated during the third trimester of pregnancy and is generally not recommended for use in the first and second trimesters, or by breastfeeding mothers. It is also not recommended for children and adolescents under 18 years of age due to insufficient clinical data. Use in the elderly or in patients with mild to moderate renal or hepatic impairment requires conditional use with close medical surveillance.

What should I know about interactions with other medicines?

Abdal Interactions with other medicines and products

The official interaction profile for Abdal (Aceclofenac) is defined by its potential for pharmacodynamic risk and exposure-modifying effects on co-administered substances, as documented by regulatory authorities.

Pharmacodynamic and Organ Toxicity Risks

Co-administration is associated with an enhanced risk of specific adverse outcomes. The use of Abdal with Anticoagulants (such as Warfarin), Corticosteroids, Anti-platelet agents, and SSRIs may enhance the documented risk of bleeding or gastrointestinal ulceration. Combinations with Diuretics or ACE Inhibitors can diminish their intended therapeutic effect and increase the risk of nephrotoxicity. An increased risk of convulsions is documented when taken with Quinolone antibiotics. Use with Ciclosporin or Tacrolimus also increases the documented risk of nephrotoxicity.

Exposure Modification and Restrictions

Abdal may officially reduce the elimination of certain drugs. This interaction can lead to increased plasma concentrations for substances such as Lithium, Cardiac Glycosides (like Digoxin), and Methotrexate, raising the potential for toxicity.

Mandatory restrictions include the formal prohibition of co-administration with other NSAIDs, including aspirin at analgesic doses. Specific timing rules apply to Mifepristone, which should not be administered for 8 to 12 days following Abdal. Close medical surveillance is advised for regular alcohol consumers due to the increased gastric bleeding risk. The elderly population and patients with hepatic or renal impairment carry a heightened documented risk profile for these interactions.

Mechanism of Action

Modulating the Prostaglandin Synthesis Pathway

The core mechanism of Abdal involves the selective inhibition of the Cyclooxygenase-2 (COX-2) enzyme. This action directly interferes with the arachidonic acid cascade, significantly reducing the excessive synthesis of Prostaglandin E₂ (PGE₂) —a primary chemical mediator that supports the propagation of inflammation and modulates nociceptor sensitivity.

Mechanism of Anti-Inflammatory Cascade Dampening

Beyond enzyme inhibition, the active ingredient is mechanistically associated with the suppression of key pro-inflammatory cytokines, such as Interleukin-1 beta (IL-1β). By modulating these upstream signaling proteins, the mechanism helps to curtail the sustained, cell-mediated processes that drive long-term inflammatory pathway activation.

Influence on Nociception and Thermoregulation

The physiological consequence of reduced PGE₂ concentration is a dual effect: it increases the threshold of peripheral nociceptors, which attenuates afferent nociceptive input, and it acts centrally within the hypothalamus to reduce pyrogenic signaling. These regulatory adjustments contribute to the modulation of nociceptive and thermoregulatory pathway activity.

Dosage and Administration Information

Administration Protocol

Abdal is an oral preparation administered as a 100 mg film-coated tablet. The medicine is intended to be swallowed whole with a sufficient quantity of liquid, and the tablet must not be crushed or chewed during administration. To support proper intake, the tablet is typically taken preferably with or immediately after food.

Standard Dosing and Frequency

The standard total daily dose for adults is 200 mg. This regimen is generally administered by taking one 100 mg tablet twice per day, once in the morning and once in the evening. The duration of use is typically limited to the lowest effective dose for the shortest period required for symptomatic control. The continued necessity for use is periodically re-evaluated.

Population-Specific Use

Specific dose adjustments apply to certain patient groups. For individuals with known hepatic (liver) impairment, the initial daily dose is 100 mg (one tablet once daily). While a specific dose change is not required for older adults, the general principle of using the lowest effective dose for the shortest duration applies. Abdal is not recommended for use in children due to a lack of clinical data in the pediatric population.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Evaluation of Clinical Endpoints

A Phase 3 trial was conducted in 500 patients with Condition A. The study focused on evaluating the drug's effect on clinical disease activity, using the DAS-28 score as a primary endpoint, and exploring patient-reported outcomes via a validated QoL (Quality of Life) questionnaire after 12 weeks.

In clinical trials, the medication was associated with a statistically significant change in QoL scores. This change was observed when compared to the baseline measurement.
Studies compared the change in pain scores and the time to initial change between the treatment and placebo groups.
Research evaluated the change in symptoms over the 6-month follow-up period. The evidence does not yet clarify whether these findings can be extrapolated to longer treatment durations.

Safety and Subgroup Analysis Scope

The study evaluated safety by assessing the incidence of adverse events (AEs) and withdrawals due to AEs.

Dose Escalation and Co-administration

Research examined the dose-response relationship between dosage and the reported incidence of AEs. One study evaluated the co-administration of the drug with NSAIDs to explore outcomes. Findings were mixed; some patients appeared to have a greater observed change in symptoms, but the rate of GI side effects was also increased.

Specific Populations

Research examined the long-term safety profile of the drug in the elderly population. The trial, which included 150 patients over the age of 65, examined safety parameters, including serious adverse events, in this older population.

One trial evaluated the drug in patients with Condition C. Studies excluded patients with a history of Kidney Disorder or specifically evaluated the safety profile in this subgroup. Research evaluated whether the combination was associated with changes in joint mobility and the onset of action. One analysis explored the magnitude and duration of the observed outcomes.

Frequently Asked Questions (FAQ)

Common questions about Abdal (FAQ)

Q: How quickly does Abdal usually start to have an effect?

A: Official information describes that the active ingredient in Abdal is rapidly absorbed after taking the tablet. Pharmacokinetic data indicates that the action of the medicine may begin within 30 minutes to 1 hour, with the highest concentration in the bloodstream typically reached within one to three hours.

Q: Do you have to take Abdal every day?

A: According to the official product information, the standard regimen is usually defined to be taken twice daily—once in the morning and once in the evening. This continuous use is the defined regimen intended to support the consistent presence of the active ingredient, which is associated with managing symptoms. However, the overall duration of use is required to be the shortest period necessary for relief.

Q: How long do people typically stay on Abdal?

A: Official instructions specify that the medicine should be used for the shortest period necessary to control symptoms. Because of this, there is no single 'typical' duration for treatment. The continued need for the medicine is subject to periodic re-evaluation by a healthcare professional.

Q: What happens if a dose of Abdal is missed?

A: Patient information typically states that if a dose is forgotten, information typically states the patient can take the next scheduled dose at the usual time. It is generally advised not to take a double dose to attempt to compensate for the missed one.

Q: Can I take vitamins or supplements with Abdal?

A: The official interaction profile lists interactions primarily with other prescription drugs. It is a general principle that information about all medications and supplements, including vitamins, should be reviewed with a health professional. This is important because some supplements may affect body functions, such as blood clotting, which can interact with this class of medicine.

Q: What should I look out for that is an unusual side effect of Abdal?

A: Regulatory documents highlight the potential for serious adverse reactions, although they are rare. Patients are advised to watch for signs of Gastrointestinal bleeding (such as black, tarry stools) or the initial appearance of a Severe Skin Reaction (like blistering or a widespread rash). The official document describes these symptoms as potentially serious, which is why patients are advised to stop taking the medicine at the first sign of a rash or mucosal lesions.

Q: Are there any common foods or drinks to avoid while using Abdal?

A: Official instructions advise that the tablet should be taken with or immediately after food to help with proper intake. Warnings also note that close monitoring is required for individuals who consume alcohol regularly, due to a documented increased risk of gastric bleeding when combined with the medicine.

Q: Does Abdal have a risk of dependence or addiction?

A: Abdal is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). The official classification and pharmacological profile of the active ingredient do not include any documented risk of dependence or addiction.

Q: What common supplements should be reviewed for interaction with Abdal?

A: The official document does not provide a comprehensive list of supplements. Regulatory documents state that interactions are a concern with agents that may affect blood clotting or impact kidney function, consistent with the documented risks of combining the medicine with anti-platelet agents or diuretics.

Q: Is Abdal used to prevent a condition or treat an existing one?

A: Abdal is officially indicated for the symptomatic relief of pain and inflammation in chronic inflammatory conditions. This function establishes its intended use as the treatment of existing symptoms rather than the prevention (prophylaxis) of a condition.

Q: What is the half-life of Abdal?

A: The half-life is a descriptive measure of how long it takes for half of the dose to be eliminated from the body. The mean plasma elimination half-life of the active ingredient in Abdal is approximately 4 to 4.3 hours, according to official pharmacokinetic data.

Q: Where can I find the official regulatory information about Abdal?

A: Official information for patients is typically found in the Patient Information Leaflet (PIL), which is included with the medicine. More detailed information approved by government drug authorities for health professionals is available in the Summary of Product Characteristics (SmPC).

Q: Does the medicine come in different strengths?

A: The standard presentation detailed in official product documents is the 100 mg film-coated tablet. While the availability of other strengths or forms may vary by region, this is the strength primarily described in the official guidance.

Q: What happens to Abdal in the body?

A: After being taken orally, the medicine is absorbed and circulated, where it acts by blocking an enzyme to reduce inflammation. The active ingredient is then metabolized, mainly in the liver, and the inactive components are primarily eliminated from the body via the urine and, to a lesser extent, the feces.

Q: Is Abdal considered a high-risk medication?

A: Abdal is a Nonsteroidal Anti-inflammatory Drug (NSAID) and is subject to official regulatory warnings common to this class of medicine. These warnings inform professionals and patients about documented serious risks, including those related to the stomach, intestines, and heart. The defined risk profile, consistent with the NSAID class, is documented in the medication's safety documentation.

Q: Can Abdal cause feelings of tiredness or fatigue?

A: Official documentation lists several central nervous system effects among the documented undesirable effects. These include occurrences of fatigue (tiredness) and drowsiness (somnolence).

Q: Does Abdal affect sleep patterns?

A: Official product information lists symptoms such as drowsiness (somnolence) and dizziness as undesirable effects. These documented symptoms are known to have the potential to influence a person’s normal sleep-wake cycle.

Q: Is it safe to drink alcohol in moderation while taking Abdal?

A: Official warnings do not define a 'safe' limit for moderate alcohol consumption. Regulatory guidance notes that close monitoring is required for regular alcohol consumers due to the documented increased risk of gastric bleeding when the two are combined.

Q: Is Abdal known to cause weight gain?

A: Official NSAID warnings reference the potential for fluid retention and oedema (swelling). An increase in body weight associated with this fluid retention is listed as a documented, though very rare, undesirable effect.

Q: Does Abdal affect blood pressure readings?

A: Fluid retention and oedema have been reported in association with this class of therapy. For this reason, appropriate monitoring and advice are required for patients with a history of hypertension (high blood pressure) or certain heart conditions, as noted in the official warnings.

Q: Can Abdal affect my ability to drive or operate machinery?

A: Official documentation advises that if a patient experiences undesirable effects such as dizziness, vertigo, drowsiness, fatigue, or visual disturbances, official documentation indicates that patients experiencing these effects are advised against driving or operating machinery. This is a standard precaution related to the medicine’s side effect profile.

Q: Is there a generic version of Abdal available?

A: Yes, the active ingredient in Abdal is Aceclofenac. The active compound is widely known and is available under its generic name, in addition to many other local and international brand names.

Q: Can I stop taking Abdal whenever I feel better?

A: While the duration of use is generally required to be the shortest period necessary for symptomatic control, official guidance states that the continued necessity for the medicine must be periodically re-evaluated by a qualified professional before any decision to stop.

Q: Is Abdal safe to use if I have kidney issues?

A: Official guidelines state that the medicine is contraindicated (prohibited) for patients with established severe renal failure. For patients with milder kidney impairment, the use is conditional and documented to require close medical surveillance.

Q: Why are there warnings about not using Abdal with certain medical conditions?

A: The official prohibitions (contraindications) are documented because using the medicine in certain circumstances creates an enhanced and unacceptable risk of adverse outcomes. These risks include Gastrointestinal bleeding/ulceration and severe organ failure (heart, liver, or kidney).

Q: How is the safety of Abdal monitored after it is approved?

A: The safety of the medicine is continuously monitored by government drug agencies through post-marketing surveillance systems (also called Pharmacovigilance). This official process systematically collects and reviews reports of adverse reactions to ensure the safety profile remains consistent over time.

How should Abdal be stored and disposed of?

Official Storage Requirements

Abdal (Aceclofenac) tablets must be stored at a temperature below 30 C (86 F) and must not be frozen to maintain product stability. Regulatory labeling mandates that the medicine be kept in its original package and blister strip to ensure protection from both light and moisture. To comply with child safety requirements, the medicine must be stored out of the sight and reach of children.

Official Disposal Instructions

Unused or expired Abdal must not be thrown away via wastewater or household waste, as indicated in official environmental disposal guidelines. Patients should consult a pharmacist for the correct method to dispose of the product in accordance with local regulations.

Abdal